Wijdenes J - Search Results

1

Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia.

Derhaschnig U, Bergmair D, Marsik C, Schlifke I, Wijdenes J, Jilma B. Derhaschnig U, et al. Among authors: wijdenes j. Crit Care Med. 2004 May;32(5):1136-40. doi: 10.1097/01.ccm.0000126265.08175.be. Crit Care Med. 2004. PMID: 15190963 Clinical Trial.

2

Interleukin-6 and its soluble receptor during acute meningococcal infections: effect of plasma or whole blood exchange.

Frieling JT, van Deuren M, Wijdenes J, van Dalen R, Bartelink AK, van der Linden CJ, Sauerwein RW. Frieling JT, et al. Among authors: wijdenes j. Crit Care Med. 1996 Nov;24(11):1801-5. doi: 10.1097/00003246-199611000-00007. Crit Care Med. 1996. PMID: 8917028

3

Pilot clinical trial of an anti-TNF alpha monoclonal antibody for the treatment of septic shock.

Boillot A, Capellier G, Racadot E, Wijdenes J, Herve P, Barale F. Boillot A, et al. Among authors: wijdenes j. Clin Intensive Care. 1995;6(2):52-6. Clin Intensive Care. 1995. PMID: 10150799 Clinical Trial.

4

Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.

Wendling D, Racadot E, Wijdenes J. Wendling D, et al. Among authors: wijdenes j. J Rheumatol. 1993 Feb;20(2):259-62. J Rheumatol. 1993. PMID: 8474061 Clinical Trial.

5

Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.

van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA. van der Pouw Kraan TC, et al. Among authors: wijdenes j. J Exp Med. 1995 Feb 1;181(2):775-9. doi: 10.1084/jem.181.2.775. J Exp Med. 1995. PMID: 7836930 Free PMC article.

6

Circulating interleukin-6 receptor in patients with sepsis syndrome.

Frieling JT, van Deuren M, Wijdenes J, van der Meer JW, Clement C, van der Linden CJ, Sauerwein RW. Frieling JT, et al. Among authors: wijdenes j. J Infect Dis. 1995 Feb;171(2):469-72. doi: 10.1093/infdis/171.2.469. J Infect Dis. 1995. PMID: 7661926 Free article.

7

Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.

Lu ZY, Zhang XG, Rodriguez C, Wijdenes J, Gu ZJ, Morel-Fournier B, Harousseau JL, Bataille R, Rossi JF, Klein B. Lu ZY, et al. Among authors: wijdenes j. Blood. 1995 May 1;85(9):2521-7. Blood. 1995. PMID: 7727780 Free article.

8

Soluble interleukin 6 receptor in biological fluids from human origin.

Frieling JT, Sauerwein RW, Wijdenes J, Hendriks T, van der Linden CJ. Frieling JT, et al. Among authors: wijdenes j. Cytokine. 1994 Jul;6(4):376-81. doi: 10.1016/1043-4666(94)90061-2. Cytokine. 1994. PMID: 7948745

9

Circulating concentrations of soluble interleukin 6 receptors gp80 and gp130 in chronic renal failure and effects of renal replacement therapy.

Frieling JT, van Hamersvelt HW, Wijdenes J, Hendriks T, Sauerwein RW, van Der Linden CJ. Frieling JT, et al. Among authors: wijdenes j. Am J Nephrol. 1999;19(5):571-5. doi: 10.1159/000013522. Am J Nephrol. 1999. PMID: 10575186

10

Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease.

Hervé P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P, Plouvier E, Stephan JL, Bourdeau H, Holler E, et al. Hervé P, et al. Among authors: wijdenes j. Blood. 1992 Jun 15;79(12):3362-8. Blood. 1992. PMID: 1596576 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

202 results

Search Page

Filters